Cita APA

Castillo, J. J., Guerrero‐Garcia, T., Baldini, F., Tchernonog, E., Cartron, G., Ninkovic, S., . . . Bibas, M. (2019). Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.

Citación estilo Chicago

Castillo, Jorge J., et al. Bortezomib Plus EPOCH Is Effective As Frontline Treatment in Patients With Plasmablastic Lymphoma. 2019.

Cita MLA

Castillo, Jorge J., et al. Bortezomib Plus EPOCH Is Effective As Frontline Treatment in Patients With Plasmablastic Lymphoma. 2019.